J. Goldman & CO LP Myovant Sciences Ltd. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Myovant Sciences Ltd. stock. As of the latest transaction made, J. Goldman & CO LP holds 12,000 shares of MYOV stock, worth $0. This represents 0.02% of its overall portfolio holdings.
Number of Shares
12,000Holding current value
$0% of portfolio
0.02%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding MYOV
# of Institutions
6Shares Held
61.3KCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA60KShares$01.49% of portfolio
-
Four Thought Financial, LLC Venice, FL1KShares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY219Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,97Shares$00.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
About Myovant Sciences Ltd.
- Ticker MYOV
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 96,802,800
- Description
- Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...